Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 14:2019:4674190.
doi: 10.1155/2019/4674190. eCollection 2019.

Scolopendra subspinipes mutilans L. Koch Ameliorates Rheumatic Heart Disease by Affecting Relative Percentages of CD4+CD25+FoxP3 Treg and CD4+IL17 T Cells

Tiechao Jiang  1   2 , Qini Zhao  1   2 , Hongyan Sun  3 , Lirong Zhang  3 , Shanshan Song  4 , Hongli Chi  5 , Hui Zhou  6
Affiliations

Scolopendra subspinipes mutilans L. Koch Ameliorates Rheumatic Heart Disease by Affecting Relative Percentages of CD4+CD25+FoxP3 Treg and CD4+IL17 T Cells

Tiechao Jiang et al. Evid Based Complement Alternat Med. .

Retraction in

Abstract

(Scolopendra subspinipes mutilans L. Koch. (SSLK) helps reduce the risk of coronary heart disease (CHD) but its effects on rheumatic heart disease (RHD) patients remain unclear. 80 RHD patients were recruited and randomly assigned into SG (to receive SSLK treatment) and CG (to receive placebo) groups, and the intervention lasted for 3 months. The following cardiac indexes were measured, including mean arterial pressure (MAP), heart rate (HR), central venous pressure (CVP), blood lactate, fatigue, shortness of breath, palpitation, and chest pain. ELISA kits were used to analyze creatine kinase isoenzyme (CK-MB), serum troponin T (cTnT), CRP, IL-1β, IL-6, and TNF-α, malondialdehyde (MDA), and superoxide dismutase (SOD). Relative percentages of CD4+CD25+FoxP3 regulatory (Treg) and CD4+IL-17 T cells were measured using flow cytometry. After 3-month therapy, SSLK intervention improved MAP, HR, CVP, fatigue, palpitation, and shortness breath of CHD patients, reduced the levels of blood lactate, CK-MB, cTnT, CRP, IL-1β, IL-6, TNF-α, MDA, and increased SOD level (p < 0.05). Meanwhile, SSLK treatment increased the percentages of CD4+CD25+FoxP3 Treg cells and reduced relative percentages of CD4+IL-17 T cells in a dose-dependent way (p < 0.05). Relative percentage of CD4+CD25+FoxP3 Treg cells had negative relationship while CD4+IL17 T cells had positive relationship with CK-MB, cTnT, CRP, and TNF-a (p < 0.01). SSLK ameliorated RHD by affecting the balance of CD4+CD25+FoxP3 Treg and CD4+IL17 T cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
ELISA analysis of the effects of SSLK on the levels of cytokines and transcription factor. (a), the effects of SSLK on serum levels of IL-1β. (b), the effects of SSLK on serum levels of IL-6. (c), the effects of SSLK on serum levels of IL-10. (d), the effects of SSLK on the levels of TGF-β. In the SG group, the patients took SSLK and in the CG group, the patients took placebo (n = 40 for each group).∗p < 0.05 via a control group.
Figure 2
Figure 2
Flow cytometry analysis of the percentage of CD4+CD25+FoxP3 Treg and CD4+IL-17 T cells in PBMCs. (a), the percentage of CD4+CD25+FoxP3 Treg cells in the CG group before placebo intervention. (b), the percentage of CD4+IL-17 T cells in the CG group before placebo intervention. (c), the percentage of CD4+CD25+ FoxP3 Treg cells in the SG group before SSLK intervention. (d), the percentage of CD4+IL-17 T cells in the SG group before SSLK intervention. (e), the percentage of CD4+CD25+FoxP3 Treg cells in the CG group after 3-month placebo intervention. (b), the percentage of CD4+IL-17 T cells in the CG group after 3-month placebo intervention. (c), the percentage of CD4+CD25+ FoxP3 Treg cells in the SG group after 3-month SSLK intervention. (d), the percentage of CD4+IL-17 T cells in the SG group after 3-month SSLK intervention. In the SG group, the patients took SSLK and in the CG group, the patients took placebo.
Figure 3
Figure 3
The effects of SSLK on the percentage of CD4+CD25+FoxP3 Tregs and CD4+IL-17 T cells in PBMCs. (a), The effects of SSLK on the percentage of CD4+IL-17 T cells in PBMCs. (b), the effects of SSLK on the percentage of CD4+CD25+FoxP3 Treg cells in PBMCs. ∗p <0.05 and ∗∗p <0.01 via the 0-μg/ml group.
Figure 4
Figure 4
The relationship between the percentage of CD4+CD25+FoxP3 Tregs and CK-MB,cTn1, CRP and TNF-α. (a), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and CK-MB. (b), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and cTn1. (c), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and CRP. (d), the relationship between the percentage of CD4+CD25+FoxP3 Tregs and TNF-α. There was a strong negative relationship between two variables if rho values < -0.5.
Figure 5
Figure 5
The relationship between the percentage of CD4+IL-17 T cells and CK-MB,cTn1, CRP, and TNF-α. (a), the relationship between the percentage of CD4+IL-17 T cells and CK-MB. (b), the relationship between the percentage of CD4+IL-17 T cells and cTn1. (c), the relationship between the percentage of CD4+IL-17 T cells and CRP. (d), the relationship between the percentage of CD4+IL-17 T cells and TNF-α. There was a strong negative relationship between two variables if rho values > 0.5.
Figure 6
Figure 6
Schematic diagram of the effects of SSLK on CHD patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yacoub M., Mayosi B., ElGuindy A., Carpentier A., Yusuf S. Eliminating acute rheumatic fever and rheumatic heart disease. The Lancet. 2017;390(10091):212–213. doi: 10.1016/S0140-6736(17)31608-2. - DOI - PubMed
    1. Makrexeni Z. M., Pepeta L. Clinical presentation and outcomes of patients with acute rheumatic fever and rheumatic heart disease seen at a tertiary hospital setting in Port Elizabeth, South Africa. Cardiovascular Journal of Africa. 2017;28(4):248–250. doi: 10.5830/CVJA-2017-019. - DOI - PMC - PubMed
    1. Teker E., Akadam-Teker A. B., Ozturk O., et al. Association between the interferon gamma 874 T/A polymorphism and the severity of valvular damage in patients with rheumatic heart disease. Biochemical Genetics. 2018;56(3):225–234. doi: 10.1007/s10528-017-9839-0. - DOI - PubMed
    1. Suzuki T., Mawatari M., Iizuka T., et al. An ineffective differential diagnosis of infective endocarditis and rheumatic heart disease after streptococcal skin and soft tissue infection. Internal Medicine. 2017;56(17):2361–2365. doi: 10.2169/internalmedicine.8411-16. - DOI - PMC - PubMed
    1. Abdullahi U., Kana S., Yakasai M., et al. Update on rheumatic heart disease in Kano: data from the Aminu Kano Teaching Hospital echocardiography registry. Nigerian Journal of Basic and Applied Sciences. 2017;14(2):127–130. doi: 10.4103/njbcs.njbcs_17_17. - DOI

Publication types